In vitro activities of the spectinomycin analog U-63366 and four quinolone derivatives against Neisseria gonorrhoeae.
The in vitro activities of the new spectinomycin analog U-63366 and four new quinolone derivatives, rosoxacin, norfloxacin, ofloxacin, and ciprofloxacin, were compared with those of penicillin, tetracycline, thiamphenicol, cefotaxime, ceftriaxone, and spectinomycin against 222 beta-lactamase-negative and 25 beta-lactamase-positive Neisseria gonorrhoeae strains. U-63366 was more active than spectinomycin, inhibiting 90% of the strains at a concentration of 2 mg/liter. Among the quinolone derivatives, ciprofloxacin was the most active compound in vitro (90% MIC, 0.002 mg/liter), followed by ofloxacin (90% MIC, 0.008 mg/liter), norfloxacin (90% MIC, 0.015 mg/liter), and rosoxacin (90% MIC, 0.03 mg/liter).
D042462:4-Quinolones; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002939:Ciprofloxacin; D008826:Microbial Sensitivity Tests; D009268:Nalidixic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D009344:Neisseria gonorrhoeae / Q000187:drug effects*; D009643:Norfloxacin; D011804:Quinolines / Q000494:pharmacology*; D015363:Quinolones; D000198:Spectinomycin / Q000031:analogs & derivatives* / Q000494:pharmacology
D042462:4-Quinolones; D000900:Anti-Bacterial Agents; D011804:Quinolines; D015363:Quinolones; D009268:Nalidixic Acid; C021083:rosoxacin; D002939:Ciprofloxacin; C043267:trospectomycin; D000198:Spectinomycin; D009643:Norfloxacin